Answers are grounded in this paper and cite their sources.
Case report shows improved glycemic control in hospitalized type 1 diabetes patients using an artificial pancreas, suggesting its clinical advantage over insulin injections.
Background To observe the efficacy and safety of artificial pancreas (Android‐hybrid closed‐loop [HCL] system) in patients with type 1 diabetes mellitus (T1DM), and to compare it with insulin multi‐injection therapy. Case presentation A patient with long course of type 1 diabetes was treated with multiple injections of insulin, Android‐HCL therapy, and sequential multiple injections of insulin. The intraday glucose fluctuation (especially after lunch, before sleep, and during sleep) of the Android‐HCL system was significantly superior to that of the sequential multi‐injection insulin therapy. The administration of artificial pancreas system (APS) could significantly reduce the occurrence of Grade 2 hypoglycemia events. Conclusion Artificial pancreases are feasible for inpatients with type 1 diabetes and may be preferable to conventional insulin therapy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: